title: Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing.
abstract: Mycophenolate mofetil (MMF), a mycophenolic acid (MPA) formulation, has improved both short- and long-term outcomes following renal transplantation, but is often associated with gastrointestinal (GI) complications that can lead to dose reduction or discontinuation, potentially jeopardizing patient outcomes. Enteric-coated mycophenolate sodium (EC-MPS) delivers equivalent MPA exposure to MMF and offers the potential to reduce GI burden (while maintaining patient safety). Here we review the efficacy of EC-MPS compared with MMF in renal transplant patients in terms of biopsy-proven acute rejection and graft loss, and examine the use of EC-MPS in newer regimens such as intensified dosing and calcineurin inhibitor minimization.
authors.affiliation: Division of Transplantation, University of Maryland School of Medicine, Baltimore, MD, USA. mcooper@smail.umaryland.edu
authors.forename: Matthew
authors.initials: M
authors.lastname: Cooper
authors.forename: Maurizio
authors.initials: M
authors.lastname: Salvadori
authors.forename: Klemens
authors.initials: K
authors.lastname: Budde
authors.forename: Frederic
authors.initials: F
authors.lastname: Oppenheimer
authors.forename: Hans
authors.initials: H
authors.lastname: Sollinger
authors.forename: Martin
authors.initials: M
authors.lastname: Zeier
mesh_terms: D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016030:Kidney Transplantation; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D013608:Tablets, Enteric-Coated / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D007166:Immunosuppressive Agents; D013608:Tablets, Enteric-Coated; D009173:Mycophenolic Acid